Background:As an acute phase protein, α1-antitrypsin (AAT) has been extensively studied in acute coronary syndrome, but it is unclear whether a relationship exists between AAT and stable angina pectoris (SAP). The purpose of the present study was to investigate the association between AAT plasma levels and SAP.Methods:Overall, 103 SAP patients diagnosed by coronary angiography and clinical manifestations and 118 control subjects matched for age and gender were enrolled in this case-control study. Plasma levels of AAT, high-sensitivity C-reactive protein (hsCRP), lipid profiles and other clinical parameters were assayed for all participants. The severity of coronary lesions was evaluated based on the Gensini score (GS) assessed by coronary angiography.Results:Positively correlated with the GS (r = 0.564, P < 0.001), the plasma AAT level in the SAP group was significantly higher than that in the control group (142.08 ± 19.61 mg/dl vs. 125.50 ± 19.67 mg/dl, P < 0.001). The plasma AAT level was an independent predictor for both SAP (odds ratio [OR] = 1.037, 95% confidence interval [CI]: 1.020–1.054, P < 0.001) and a high GS (OR = 1.087, 95% CI: 1.051–1.124, P < 0.001) in a multivariate logistic regression model. In the receiver operating characteristic curve analysis, plasma AAT level was found to have a larger area under the curve (AUC) for predicting a high GS (AUC = 0.858, 95% CI: 0.788–0.929, P < 0.001) than that of hsCRP (AUC = 0.665, 95% CI: 0.557–0.773, P = 0.006; Z = 2.9363, P < 0.001), with an optimal cut-off value of 137.85 mg/dl (sensitivity: 94.3%, specificity: 68.2%).Conclusions:Plasma AAT levels correlate with both the presence and severity of coronary stenosis in patients with SAP, suggesting that it could be a potential predictive marker of severe stenosis in SAP patients.
Background: The efficacy of traditional Chinese exercise (TCE)-based intervention in the improvement of physiological indicators and quality of life in patients with coronary heart disease (CHD) is controversial. Method: Five databases were systematically searched for relevant articles published from inception to February 2023. Controlled trials examining TCE intervention in patients with CHD. The treatment effects were estimated using a random-effect meta-analysis model with standardized mean differences (Hedges g). The categorical and continuous variables were used to conduct moderator analyses. Two investigators independently screened abstracts and full-text articles and graded the certainty of evidence based on the Grading of Recommendations Assessment, Development and Evaluation approach. This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (identifier CRD42023401934). Result: Ten studies involving a total of 718 participants were included in the final analysis. In the physiological indicators outcomes, the meta-analytic findings revealed large and significant improvements in systolic blood pressure (g = 0.78, 95% confidence interval [CI] = 0.51–1.05, P = .00, I 2 = 98%), diastolic blood pressure (g = 0.90, 95% CI = 0.61–1.20, P = .00, I 2 = 98%) and body mass index (g = 1.05, 95% CI = 0.75–1.34, P = .00, I 2 = 99%), small and significant improvements in heart rate (g = 0.28, 95% CI = 0.01–0.54, P = .04, I 2 = 98%) and ventilatory equivalents/carbon dioxide (g = −1.10, 95% CI = −1.47 to −0.74, P = .00, I 2 = 96%). In the quality of life outcomes, the findings revealed small and significant improvements in physical functioning (g = −3.01, 95% CI = −3.45 to −2.57, P = .00, I 2 = 96%), bodily pain (g = −2.16, 95% CI = −2.57 to −1.74, P = .00, I 2 = 98%), vitality (g = −3.67, 95% CI = −4.16 to −3.16, P = .00, I 2 = 97%) and mental health (g = −1.23, 95% CI = −1.771 to −0.692, P = .00, I 2 = 99%). The moderator shows that the effects of TCE on physiological indicators and quality of life were moderated by PEDro score, type of exercise, exercise frequency, exercise duration, and number of sessions. Conclusion: TCE intervention is a beneficial nonpharmacological approach to improving physiological indicators in patients with CHD, especially in systolic blood pressure, diastolic blood pressure, and body mass index. However, there was no significant effect on quality of life. Our findings require broader clinical trials and higher-quality study designs to strengthen the evidence.
Purpose To evaluate the effect of a single intravenous low-dose esketamine combined with labour analgesia on the occurrence of postpartum depression in patients with spontaneous labour.Methods Female patients in labour were divided into a group of esketamine combined with labour analgesia (group A, n = 116), a group with labour analgesia alone (group B, n = 132) and a control group (group C, n = 51) according to the mode of analgesia. The Edinburgh Postpartum Depression Scale (EPDS) and visual analog scale (VAS) scores were collected at different time points for all three groups. Serum was also collected from patients before and after delivery to detect serum sex hormone changes.Results This clinical study was a prospective, randomised, double-blind trial. A total of 299 patients were enrolled in the study. Cross-sectional analysis showed no significant differences in EPDS scores or incidence of depression between the three groups in postpartum period, or at 1, 7 or 42 days postpartum. There were no statistically significant differences in VAS scores at 2 hours postpartum, 1 day, 2 days and 7 days postpartum. No significant differences were seen in the levels of oestrogen, progesterone, 5hydroxytryptamine and serum cortisol before delivery between the three groups. After delivery, serum cortisol levels were higher in the labour analgesia alone group than in the esketamine combined with labour analgesia group and the control group (P < 0.001). Longitudinal analysis showed that EPDS and VAS scores improved significantly over time in postpartum period for both combined esketamine and labour analgesia alone (P < 0.001), but no significant change was seen in the control group. This improvement was possibly associated with a decrease in postpartum oestrogen levels and an increase in serum cortisol levels (P < 0.001).Conclusion In this study, the combination of esketamine with labour analgesia did not reduce the incidence of depression and VAS scores at 1, 7 or 42 days postpartum.
This study aimed to validate the accuracy of DBP-6279B, an automated inflationary oscillometric upper-arm blood pressure (BP) monitor, in the sitting position according to the AAMI/ESH/ISO (81060-2 : 2018 + Amd.1 : 2020) universal standard protocol. SBPs and DBPs were measured simultaneously on the same arm in 88 adults (female : male = 47 : 41) with a mean age of 56.85 years using a mercury sphygmomanometer (two observers) and a DBP-6279B device (one supervisor). The AAMI/ESH/ISO 81060-2 : 2018 and Amd.1 : 2020 universal standards for the validation of BP-measuring devices in adults and adolescents were followed. A total of 259 valid pairs of data were used in the analysis. According to Criterion 1, the mean difference of SBP between the test device (DBP-6279B) and the reference device (the mercury sphygmomanometer) was 0.75 mmHg, with a SD of 7.66 mmHg. The mean difference in DBP was 1.13 mmHg, with a SD of 6.14 mmHg. The mean difference of both SBP and DBP was less than 5 mmHg, and the SD was less than 8 mmHg, which met the requirements. According to Criterion 2, the mean difference of SBP between the test device and the reference device was 0.85 mmHg, and the SD was 6.56 mmHg, which was less than 6.88 mmHg and met the requirements. The mean difference in DBP was 1.27 mmHg, and the SD was 5.42 mmHg, which was less than 6.82 mmHg and met the requirements. DBP-6279B fulfilled the requirements of the AAMI/ESH/ISO universal standard (ISO 81060-2 : 2018 + Amd.1 : 2020); hence, it can be recommended for both clinical and self/home BP measurement in adults and adolescents.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.